News Category: Regulatory news
No reports of current shortages or supply disruptions of medicines marketed in the EU due to Covid-19
The European Medicines Agency (EMA), the European Commission and the national competent authorities in the Member States are closely monitoring the potential impact of the outbreak of the novel coronavirus disease (COVID-19) on pharmaceutical supply chains into the European Union (EU).
The first meeting of the EU Executive Steering Group on shortages of medicines caused by major events has been organised to discuss measures aimed at addressing the potential impact of the outbreak of COVID-19 on the supply of medicines in the EU. The mandate of this group is to provide strategic leadership for urgent and coordinated action within the EU in case a crisis caused by major events, such as the COVID-19 outbreak, risks impacting the supply of medicinal products for human and veterinary use.
Further information is available from the EMA website.